ZielBio Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Out of Business

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Out of Business

ZielBio General Information

Description

Operator of a clinical-stage biotechnology company intended to identify druggable and specific targets that have the potential to radically change the way medical professionals treat disease. The company's technology combines the power of functional, throughput screening with large content data analytics to identify high-value targets, including a lead compound, which is a proprietary humanized monoclonal antibody against cell surface plectin, enabling medical practitioners to acquire a potential drug that can be used to treat a range of cancers.

Contact Information

Website
www.zielbio.com
Formerly Known As
iTiHealth
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 1317 Carlton Avenue
  • Suite 200
  • Charlottesville, VA 22902
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1317 Carlton Avenue
  • Suite 200
  • Charlottesville, VA 22902
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ZielBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Out of Business 03-Jul-2025 Completed Out of Business
5. Later Stage VC 27-Sep-2022 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series A) 16-Sep-2019 Completed Clinical Trials - Phase 1
3. Seed Round 16-Jun-2017 Completed Pre-Clinical Trials
2. Grant 31-Jul-2013 $1.5M $110K Completed Pre-Clinical Trials
1. Seed Round 01-Jan-2011 $110K $110K Completed Startup
To view ZielBio’s complete valuation and funding history, request access »

ZielBio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-1
Series A
Seed 257,679 $0.001000 $3.19 $3.19 1x $3.19 1.94%
To view ZielBio’s complete cap table history, request access »

ZielBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biotechnology company intended to identify druggable and specific targets that have the pot
Biotechnology
Charlottesville, VA
10 As of 2022

Maastricht, Netherlands
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ZielBio Competitors (75)

One of ZielBio’s 75 competitors is Cristal Therapeutics, a Venture Capital-Backed company based in Maastricht, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
AsherBio Venture Capital-Backed South San Francisco, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Pure MHC Formerly VC-backed Austin, TX
You’re viewing 5 of 75 competitors. Get the full list »

ZielBio Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

ZielBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022377061-A1 Cancer specific plectin-1 specific antibodies and methods of use thereof Inactive 29-Oct-2021
CA-3235789-A1 Cancer specific plectin-1 specific antibodies and methods of use thereof Pending 29-Oct-2021
EP-4423125-A1 Cancer specific plectin-1 specific antibodies and methods of use thereof Inactive 29-Oct-2021
US-20250011418-A1 Cancer specific plectin-1 specific antibodies and methods of use thereof Inactive 29-Oct-2021
WO-2023077099-A1 Cancer specific plectin-1 specific antibodies and methods of use thereof Inactive 29-Oct-2021 C07K16/28
To view ZielBio’s complete patent history, request access »

ZielBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

ZielBio FAQs

  • When was ZielBio founded?

    ZielBio was founded in 2010.

  • Where is ZielBio headquartered?

    ZielBio is headquartered in Charlottesville, VA.

  • What is the size of ZielBio?

    ZielBio has 10 total employees.

  • What industry is ZielBio in?

    ZielBio’s primary industry is Biotechnology.

  • Is ZielBio a private or public company?

    ZielBio is a Private company.

  • What is ZielBio’s current revenue?

    The current revenue for ZielBio is .

  • How much funding has ZielBio raised over time?

    ZielBio has raised $41M.

  • Who are ZielBio’s competitors?

    Cristal Therapeutics, AsherBio, Adaptimmune Therapeutics, CytomX Therapeutics, and Pure MHC are some of the 75 competitors of ZielBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process